Coumarin 7 is a fluorescent dye with a high quantum yield and excellent photostability. It is commonly used in fluorescence microscopy, flow cytometry, and other biological applications. Coumarin 7 is synthesized through a multi-step process involving the condensation of salicylaldehyde with a suitable aromatic ketone. The resulting coumarin derivative can then be further modified to obtain Coumarin 7. This dye exhibits strong absorption in the ultraviolet region and emits green fluorescence upon excitation. The high quantum yield and photostability of Coumarin 7 make it a valuable tool for imaging and studying cellular processes. Its ability to penetrate cell membranes allows researchers to track the movement and distribution of molecules within cells. Coumarin 7 is also used in various sensing applications, such as detecting specific ions or molecules. The unique spectral properties and high sensitivity of this dye make it a powerful tool for studying biological systems. Its applications extend to areas like cell biology, bioimaging, and drug discovery. Coumarin 7 is widely studied because of its potential applications in various fields, including biomedical research, environmental monitoring, and material science. Researchers are constantly exploring new ways to use Coumarin 7 for various purposes. The high quantum yield and photostability of Coumarin 7 make it a valuable tool for researchers studying various aspects of biology and chemistry.'
coumarin 7: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 94381 |
| CHEMBL ID | 374632 |
| SCHEMBL ID | 180716 |
| MeSH ID | M0506876 |
| Synonym |
|---|
| coumarin, |
| BIDD:GT0472 |
| AKOS000415301 |
| OPREA1_440779 |
| nsc-303254 |
| coumarin, 3-(2-benzimidazolyl)-7-(diethylamino)- |
| 2h-1-benzopyran-2-one, 3-(1h-benzimidazol-2-yl)-7-(diethylamino)- |
| 3-(2-benzimidazolyl)-7-(diethylamino)coumarin |
| coumarin 7 |
| nsc303254 |
| 27425-55-4 |
| 3-(1h-benzoimidazol-2-yl)-7-diethylamino-chromen-2-one |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)-2h-chromen-2-one |
| ENAMINE_000185 |
| CBDIVE_006555 |
| smr000103015 |
| MLS000106044 , |
| coumarin 7, 98% |
| STK325581 |
| B2111 |
| KUC105942N |
| KUC105942 |
| ksc-16-133 |
| CHEMBL374632 |
| cid 94381 |
| HMS1394I09 |
| HMS2467L12 |
| 3-(1h-1,3-benzodiazol-2-yl)-7-(diethylamino)-2h-chromen-2-one |
| einecs 248-451-4 |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)-2-benzopyrone |
| 3-(benzimidazol-2-yl)-7-diethylaminocoumarin |
| nsc 303254 |
| FT-0624079 |
| 3-(1h-1,3-benzodiazol-2-yl)-7-(diethylamino)chromen-2-one |
| SCHEMBL180716 |
| REGID_FOR_CID_94381 |
| DTXSID4067309 |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)-1-benzopyran-2-one |
| bdbm37601 |
| cid_94381 |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)coumarin |
| coumarin7 |
| W-110701 |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)-2h-chromen-2-one # |
| 3-(benzimidazol-2-yl)-7-(diethylamino)coumarin |
| 3-(1h-benzo[d]imidazol-2-yl)-7-(diethylamino)-2h-chromen-2-one |
| mfcd00051348 |
| 12239-58-6 |
| disperse yellow 82 |
| c.i. disperse yellow 82 |
| sr-01000389310 |
| SR-01000389310-1 |
| AS-71890 |
| Z56758388 |
| coumarin-7 |
| yellow 8gff |
| 3-(2'-benzimidazolyl)-7-(diethylamino)coumarin |
| disperse yellow 8gff |
| terasil brilliant flavine 8gff |
| VX3Q255SG5 |
| d820 savannah yellow |
| 3-(1h-benzimidazol-2-yl)-7-(diethylamino)-2h-1-benzopyran-2-one |
| fluorescent yellow 10g |
| sumikaron brilliant flavine s 10g |
| 3-(benzimidazol-2-yl)-7-diethylamino-2h-benzopyran-2-one |
| F0266-2430 |
| HY-125750 |
| AMY10383 |
| BRD-K85676811-001-08-2 |
| CS-0094880 |
| T70702 |
| SY051291 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We formulated nano-encapsulation of a naturally occurring coumarin-scopoletin (7-hydroxy-6-methoxy coumarin, HMC, C(10)H(8)O(4)), isolated from plant Gelsemium sempervirens having anticancer potentials, with a bio-adhesive agent -polylactic-co-glycolic acid (PLGA) and tested if its cellular uptake, bioavailability and apoptotic (anticancer) potentials could thus be increased vis-a-vis unencapsulated HMC." | ( Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. Bhattacharyya, SS; Boujedaini, N; Khuda-Bukhsh, AR; Paul, S, 2010) | 0.36 |
| Product Category | Products |
|---|---|
| Beauty & Personal Care | 36 |
| Household Essentials | 8 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Breast cancer type 1 susceptibility protein | Homo sapiens (human) | Potency | 0.1259 | 1.2589 | 20.4409 | 39.8107 | AID875 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 0.0577 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.1647 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 1.2589 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 12.5893 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.2000 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 1.5849 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 0.7079 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 6.3096 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| PINK1 | Homo sapiens (human) | Potency | 1.7783 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 10.0000 | 0.8913 | 10.4328 | 20.5750 | AID1379 |
| Parkin | Homo sapiens (human) | Potency | 1.7783 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 14.2438 | 0.7079 | 25.1119 | 41.2351 | AID485349; AID493185; AID493218 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.2818 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 0.7943 | 0.3162 | 9.0861 | 31.6228 | AID925 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 0.3571 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 0.3162 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.5717 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 100.0000 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 0.4301 | 0.6561 | 9.4520 | 25.1189 | AID463254; AID927 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.1000 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 2.5119 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.5717 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 0.4467 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 15.1014 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 15.8489 | 0.1298 | 10.8331 | 32.6090 | AID493005 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 7.0795 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 5.5810 | 0.0079 | 8.2332 | 1,122.0200 | AID2551; AID2762; AID2763 |
| geminin | Homo sapiens (human) | Potency | 4.6415 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 7.0795 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 3.5481 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 0.1585 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 1.5849 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 1.1220 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5893 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 64.3552 | 6.3096 | 60.2008 | 112.2020 | AID720707; AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 2.2387 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 0.3162 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 0.3162 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Caspase-7 | Homo sapiens (human) | Potency | 0.1585 | 3.9811 | 18.5856 | 31.6228 | AID889 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 0.1995 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 89.1251 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| metallo beta-lactamase | Pseudomonas aeruginosa | IC50 (µMol) | 2.7280 | 0.0339 | 2.9100 | 6.2480 | AID2754 |
| Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 1.6200 | 0.4000 | 7.1344 | 54.0000 | AID1418 |
| PTK2B protein tyrosine kinase 2 beta | Homo sapiens (human) | IC50 (µMol) | 2.3240 | 1.5370 | 4.0805 | 6.9220 | AID1641 |
| Valosin-containing protein | Homo sapiens (human) | IC50 (µMol) | 1.4000 | 0.1100 | 6.0187 | 28.0000 | AID488828 |
| metallo-beta-lactamase IMP-1 | Pseudomonas aeruginosa | IC50 (µMol) | 3.2410 | 3.2410 | 5.9685 | 8.6960 | AID2756 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.6200 | 0.0005 | 2.7739 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.6200 | 0.0005 | 2.8919 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.6200 | 0.0005 | 2.7478 | 25.1700 | AID1418 |
| Luciferin 4-monooxygenase | Photinus pyralis (common eastern firefly) | IC50 (µMol) | 3.0280 | 0.0589 | 3.1426 | 10.0000 | AID328181; AID328182; AID328183; AID328185; AID328186 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.6200 | 0.0005 | 2.7802 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.6200 | 0.0005 | 3.3142 | 49.5000 | AID1418 |
| B1 bradykinin receptor | Homo sapiens (human) | IC50 (µMol) | 3.2410 | 0.0009 | 1.6209 | 3.2410 | AID2756 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 0.7091 | 0.7091 | 5.0549 | 7.7510 | AID2755 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| matrix metalloproteinase 1, partial | Homo sapiens (human) | EC50 (µMol) | 1.0600 | 1.0600 | 10.7594 | 27.6000 | AID618 |
| voltage-dependent T-type calcium channel subunit alpha-1H isoform a | Homo sapiens (human) | EC50 (µMol) | 0.4340 | 0.4340 | 4.8275 | 13.3000 | AID489005 |
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1198908 | Inhibition of full-length X4 tropic HIV-1 clone pNL4-3 Vif/human APOBEC3G complex transfected in human 293T cells measured at 50 uM after 48 hrs by GFP-based fluorescence assay relative to control | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein. |
| AID270397 | Antiproliferative activity against human U87 MG cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID328181 | Inhibition of Photinus pyralis luciferase by PK-Light assay | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270401 | Antiproliferative activity against human SiHa cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID328184 | Inhibition of luciferase Photuris pennsylvanica by Promega Kinase-Glo assay | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270398 | Antiproliferative activity against mouse B16 cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID328183 | Inhibition of Photinus pyralis luciferase by Easy lite assay | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID328187 | Inhibition of Renilla reniformis luciferase | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270400 | Antiproliferative activity against human DLD1 cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID328185 | Inhibition of Photinus pyralis luciferase by Steady-Glo reporter gene assay | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270402 | Antiproliferative activity against mouse NIH3T3 cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID328186 | Inhibition of Photinus pyralis luciferase by BrightGlo reporter gene assay | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270403 | Antiproliferative activity against HUVEC cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID1198909 | Antiviral activity against X4 tropic HIV-1 clone pNL4-3 infected in H9 cells assessed as reduction in p24 antigen after 4 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein. |
| AID1198930 | Cytotoxicity against human H9 cells by MTS assay | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein. |
| AID328188 | Inhibition of Photinus pyralis luciferase at 0.04 uM | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID328182 | Inhibition of Photinus pyralis luciferase | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Characterization of chemical libraries for luciferase inhibitory activity. |
| AID270399 | Antiproliferative activity against human HeLa cell line | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Synthesis and anti-angiogenesis activity of coumarin derivatives. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (50.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||